ALXO logo

ALXO
Alx Oncology Holdings Inc

1,250
Mkt Cap
$223.73M
Volume
1.24M
52W High
$2.66
52W Low
$0.404
PE Ratio
-0.89
ALXO Fundamentals
Price
$1.69
Prev Close
$1.70
Open
$1.71
50D MA
$1.97
Beta
1.45
Avg. Volume
1.21M
EPS (Annual)
-$1.90
P/B
3.54
Rev/Employee
$0.00
$30.61
Loading...
Loading...
News
all
press releases
ALX Oncology (ALXO) to Release Quarterly Earnings on Thursday
ALX Oncology (NASDAQ:ALXO) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-alx-oncology-holdings-inc-stock...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded ALX Oncology from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·14d ago
News Placeholder
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
Zacks·16d ago
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat·19d ago
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...
MarketBeat·20d ago
News Placeholder
ALX Oncology (NASDAQ:ALXO) CEO Sells $26,714.87 in Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the company's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $2.17, for a total value of $26,714.87. Following the transaction, the chief...
MarketBeat·1mo ago
News Placeholder
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the firm's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an...
MarketBeat·1mo ago
News Placeholder
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO)
Wells Fargo & Company initiated coverage on ALX Oncology in a research note on Thursday. They issued an "overweight" rating and a $5.00 target price for the company...
MarketBeat·1mo ago
News Placeholder
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Zacks·1mo ago
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are covering the company...
MarketBeat·2mo ago
<
1
2
...
>

Latest ALXO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.